The content on this site is intended for healthcare professionals only
Prof Fabrice Andre talks to ecancer about identifying patients with a high risk of recurrence at IMPAKT 2012 in Brussels, May 2012.
The importance of identifying high risk patients is not just discovering which are the most susceptible to relapse, but to avoid giving a patient a therapy that will have a low effect as well.
Prof Andre notes that by using protein based and prognostic biomarkers, the best possible therapy with the lowest risk of relapse, can be identified.
The second challenge that Prof Andre addresses is how to bridge the gap between research settings and clinical practice.
Filming Supported by Amgen
The added value of integrative medicine
Insights into germline genetic screening of breast cancer patients
Multiple myeloma In Rwanda: The need for further research
GIST tumours and soft tissue sarcomas
Genomic testing: Awareness and effective communication between healthcare professionals and patients
The Southeast Asian Breast Cancer Symposium; background, aims and successes
Advancing breast cancer treatment in Uganda by improving molecular testing
Somatic mutation profile of breast cancer in Uganda
Low-cost detection and treatment strategies for breast cancer patients in LMICs
